The Pfizer Breakthrough Growth Initiative, launched in June, makes investments in biotech companies focusing on internal medicine, inflammation and immunology, oncology, rare diseases and vaccines. Pfizer plans to invest up to $500 million in biotechnology companies through the initiative.
Below are the first four companies Pfizer invested in:
- Bedford, Mass.-based Homology Medicines ($60 million)
- Cambridge, Mass.-based Trillium Therapeutics ($25 million)
- Cambridge, Mass.-based Vedanta Biosciences ($25 million)
- Vancouver-based ESSA Pharma ($10 million)
More articles on pharmacy:
Most successful vaccine rollouts in US: 4 state strategies
Utah pharmacy CEO charged for alleged illegal hydroxychloroquine importation
Health officials investigating death of Miami physician shortly after getting Pfizer vaccine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.